Management of toxicities of immune checkpoint inhibitors.
about
Focus on Nivolumab in NSCLCThe role of immune checkpoint inhibition in the treatment of ovarian cancerDrug-induced liver injury: Advances in mechanistic understanding that will inform risk management.New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management.Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis.Nivolumab-associated acute glomerulonephritis: a case report and literature review.Design of short peptides to block BTLA/HVEM interactions for promoting anticancer T-cell responses.Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma.PD-1 inhibitors increase the incidence and risk of pneumonitis in cancer patients in a dose-independent manner: a meta-analysis.Checkpoint inhibitors in advanced melanoma: effect on the field of immunotherapy.Immunotherapy for oesophagogastric cancer.Challenges in vaccine therapy in hematological malignancies and strategies to overcome them.Checkpoint Inhibitors in Head and Neck Cancer: Rationale, Clinical Activity, and Potential Biomarkers.Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer.Nivolumab in the treatment of metastatic squamous non-small cell lung cancer: a review of the evidence.Oncolytic viruses-immunotherapeutics on the rise.Cancer therapies in HIV cure research.Nivolumab in melanoma.Palliative Care of Cancer in the Older Patient.Anti-PD-1/PD-L1 antibodies in non-small cell lung cancer: the era of immunotherapy.Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathiesDiverse types of dermatologic toxicities from immune checkpoint blockade therapy.Immune-Related Adverse Effects of Cancer Immunotherapy- Implications for Rheumatology.The histopathological evaluation of drug-induced liver injury.Renal complications of immune checkpoint blockade.Targeting TGF-β Signaling for Therapeutic Gain.Antigen Loss Variants: Catching Hold of Escaping Foes.A case of nivolumab-related cholangitis and literature review: how to look for the right tools for a correct diagnosis of this rare immune-related adverse event.Myasthenia gravis induced by nivolumab in patients with non-small-cell lung cancer: a case report and literature review.Endocrine toxicity of immune checkpoint inhibitors: essential crosstalk between endocrinologists and oncologists.Tubulointerstitial nephritis as adverse effect of programmed cell death 1 inhibitor, nivolumab, showed distinct histological findings.[Adverse effects of immunotherapy : Clinical aspects, radiological and nuclear medicine results].Pembrolizumab-induced pneumonitis.Histopathological aspects of cutaneous erythematous-papular eruptions induced by immune checkpoint inhibitors for the treatment of metastatic melanoma.PD-1 inhibitor gastroenterocolitis: case series and appraisal of 'immunomodulatory gastroenterocolitis'.Imaging Features of Toxicities by Immune Checkpoint Inhibitors in Cancer Therapy.Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer.Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitorsSevere Esophagitis and Gastritis from Nivolumab Therapy.Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
P2860
Q28073759-F10FD13B-09A5-481E-B3E4-F7DD4C74E0CFQ28077924-BBA56890-5722-4D7C-A329-BC2AD94BBC06Q30241050-5DD3FBE9-A0D6-41FC-ABCD-1536FCD42000Q33564645-6323C89F-8A82-48E9-83F8-CA5C8EC8FCBCQ33607108-A6A227F1-81DF-461B-A6EA-D0C7D7FCA040Q36201404-AF7CDCCE-A317-4340-9B56-DF6AFAEF8136Q36395860-D6E21FAE-BA5F-4C88-94C4-27E51E30F479Q36951236-848235AD-4CE0-45AD-887F-93563051550EQ37685959-743BB34E-71C6-459E-86A6-79EA4AF9CC37Q38672084-8F7BDE49-5E75-4BAA-A8E2-0CD2E57BC230Q38842511-51C0220F-D6A4-4A0A-B7D9-A0A977E6A255Q38843235-EC75D0BC-49A1-474E-A9EA-EFCBCB979433Q38868396-5DE44D8E-8940-4FFF-89C1-C4D81E0A8F7CQ38870763-6DCE3885-1260-40F0-8CDD-44B348BEBFFDQ38915130-6C45EE33-7B2A-480B-A268-02AC82FA1E45Q38919107-439AB1D2-7093-4E6F-A4F4-8DBAD242DBDFQ38949445-6C3EFEB0-13E0-428C-AC0A-33745E73939BQ38989508-BDE7B661-7F4B-48F8-9458-EC6C395213CFQ38998323-BA1D009B-9075-44AE-8344-2281AB20AF80Q39007525-ECA0040E-2F32-49A4-B597-9BF1452453E3Q39010566-74746735-8978-4433-9502-D66BC37D5D63Q39012299-28FF9643-B082-43AC-AA1D-E95238F932EFQ39021248-CF53F6C1-DA1F-4967-9CEB-F54C4A32BC24Q39037640-743C917F-8A53-43EE-A1E2-633C3EB6CDC0Q39131602-C8E011D7-2DCE-41E6-9028-A484DACB8DEAQ39155151-93EA2E9F-CF30-4D60-84C5-8D4B3F40BC73Q39175440-6DF4BA95-A78A-4212-9351-07FCF66677B2Q39384997-236B4507-BFF5-4F46-98AE-36021218E5DDQ39398054-1D6EC67B-D576-4291-AD3C-A6B2109EC795Q39441719-7A4355B0-A3EC-4AAE-9BCE-953880272B46Q40076388-2F96AA68-FF2C-43B7-9F6F-FFB13B9C07CAQ40124225-4449E140-23B2-4407-9941-F97C1974AF54Q40222948-17453988-E8EC-401F-A42B-A519DB10CF42Q40340021-BFA455CC-515D-47FA-AFFD-04D7B58B1F5FQ40400994-BD4D34CF-6720-4876-9256-3BB212761055Q41669891-4F1E1FBB-3639-4FA3-A361-19437B2F5C4CQ41722598-AFE9B54C-B564-4A5C-91B8-58C0C0380680Q41831841-BB1E3374-923B-443E-85E9-4732DC530E95Q41884178-A5C4DCFC-B2C4-46B4-A387-33AEE353ADBAQ42264315-B5697A6E-4D05-4C2F-BF12-1704DF8E2D7E
P2860
Management of toxicities of immune checkpoint inhibitors.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Management of toxicities of immune checkpoint inhibitors.
@en
type
label
Management of toxicities of immune checkpoint inhibitors.
@en
prefLabel
Management of toxicities of immune checkpoint inhibitors.
@en
P1476
Management of toxicities of immune checkpoint inhibitors
@en
P2093
James Larkin
Stefan Diem
P356
10.1016/J.CTRV.2016.02.001
P577
2016-02-06T00:00:00Z